Boehringer Targets High Unmet Need With Spesolimab Filing
Could Be First EU Approved Drug For Generalized Pustular Psoriasis Flares
Boehringer Ingelheim files spesolimab in the EU, where it is a forerunner in the race to fill the unmet need in generalized pustular psoriasis flares.
You may also be interested in...
After the 14 March announcement that the IL-36R agonist failed in an acne study, it appears to have better chances in generalized pustular psoriasis, an underserved orphan indication where the target is already validated.
Major R&D efforts in immuno-dermatology produced multiple novel candidates in atopic dermatitis and psoriasis, while alopecia areata and vitiligo might see first therapies and JAK safety and COVID-19 logjams resolve.
Keeping Track: Immunology Drives US FDA Action, With Approvals For AZ/Amgen’s Tezspire, Argenx’s Vyvgart, And New JAK Uses
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker